ImmunityBio Inc Ordinary Shares IBRX 深 滬
等待開盤 09-26 09:30:00 美东时间
2.4222
-0.078
-3.11%
華盛通- 最 高2.4588
- 今 開2.44
- 成交量 425.91万股
- 最 低 2.38
- 昨 收 2.50
- 總市值 22.89亿
- 52周最高 7.48
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 1.83
- 委 比 -38.62%
- 總股本 9.45亿
- 歷史最高 45.42
- 量 比 0.77
- 振 幅 3.15%
- 歷史最低 0.93
- 每 手 1
- 風險率 0.85%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Cancer Immunotherapy Surge Drives $258B Market as FDA Accelerates Approvals
Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, Sept. 16, 2025 /PRNewswire/ -- USA News Group News Commentary – The FDA's accelerated approval of two oncology treatments in August...
09-17 00:29
美股大行评级 | 最高400美元！大行纷纷连夜上调甲骨文目标价；新思科技则惨遭多家大行下调目标价
今日重点评级关注：瑞银：上调Gossamer Bio评级至"买入"，目标价从1.25美元升至9美元；Canaccord Genuity：维持Corcept Therapeutics"买入"评级，目标价从137美元升至140美元
09-11 10:06
ImmunityBio Announces Paradigm Changing Findings From Phase 2 QUILT-3.055 Study, Showing ANKTIVA Reverses Lymphopenia In Patients With Checkpoint Inhibitor-Resistant Advanced NSCLC, With Reversal Resulting In Significant Prolonged mOS
Severe lymphopenia, an adverse treatment effect associated with chemotherapy, radiotherapy, and immunotherapy, significantly lowers overall survival in non-small cell lung cancer and multiple types of cancer.1,2With
09-08 20:35
FDA Tightens Survival Standards as Cancer Drug Pipeline Hits $866B Market Milestone
USA News Group News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, Aug. 28, 2025 /PRNewswire/ -- Federal budget cuts have put pressure on cancer research efforts in th...
08-28 22:44
What's Going On With ImmunityBio Shares Tuesday?
ImmunityBio shares are trading higher Tuesday after the company announced its chemotherapy-free combination showed 100% disease control results and is planning a Phase 2 trial.
08-27 00:33
ImmunityBio shares are trading higher after the company announced it has opened a new Phase 2 study to assess the BioShield platform.
ImmunityBio shares are trading higher after the company announced it has opened...
08-21 20:09
D. Boral Capital Maintains Buy on ImmunityBio, Maintains $24 Price Target
D. Boral Capital analyst Jason Kolbert maintains ImmunityBio (NASDAQ:IBRX) with a Buy and maintains $24 price target.
08-14 20:35
ImmunityBio higher after early-stage trial results for cell therapy in lymphoma
Shares of ImmunityBio (NASDAQ:IBRX) traded higher on Wednesday after the immunotherapy developer disclosed early-stage trial results for its natural killer cell therapy candidate in patients with a fo...
08-13 22:34
ImmunityBio Reports Announced QUILT-106 Phase I Trial
Single-agent CD19 CAR-NK cell therapy achieved a complete response in third-line Waldenstrom macroglobulinemia (WM), a type of non-Hodgkin lymphomaSecond patient maintains an ongoing complete response at six months with
08-13 20:32
ImmunityBio's ANKTIVA Now Available At Houston VA, Offering New Bladder Cancer Treatment For Veterans
ImmunityBio, Inc. ((IBRX), a leading immunotherapy company, today announced the Michael E. DeBakey Department of Veterans Affairs (VA) Medical Center in Houston recently became the first VA hospital in the Houston region
08-11 20:33
